 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C22H16ClFN6O |
| Molar mass | 434.86 g·mol−1 |
| 3D model (JSmol) | |
| |
TROX-1 is a drug which acts as a potentblocker of the Cav2 typecalcium channels. It was developed as a potentialanalgesic after the discovery that the selectiveCav2.2 blockerziconotide is an active analgesic with similar efficacy to strongopioid drugs. Unlike ziconotide, TROX-1 is not so selective, and also blocks theCav2.1 andCav2.3 calcium channel subtypes, but it has the great advantage of being orally active, whereas ziconotide must be administeredintrathecally, by injection into the spinal fluid. In animal studies of TROX-1, analgesic effects were observed with similar efficacy toNSAIDs such asnaproxen ordiclofenac, and anti-allodynia effects equivalent topregabalin orduloxetine.[1][2][3]
 | Thisdrug article relating to thecardiovascular system is astub. You can help Wikipedia byexpanding it. |
